From CommunityDispatch.com

CDC Health Advisory Notices & Announcements
CDC Update: Recommendations for Using Antiviral Agents for Influenza for the 2006-07 Influenza Season
By Center for Disease Control and Prevention
Sep 27, 2006, 07:49

 

 

 

 

 

Antiviral Medications for Influenza

Updated September 26, 2006

  • E-mail this page
  • Printer-friendly version

NOTE: The text below is taken from Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (MMWR 2006 Jul 28;55(RR10):1-42).

Recommendations for Using Antiviral Agents for Influenza for the 2006-07 Influenza Season

Although annual vaccination is the primary strategy for preventing complications of influenza virus infections, antiviral medications with activity against influenza viruses can be effective for the chemoprophylaxis and treatment of influenza. Four licensed influenza antiviral agents are available in the United States: amantadine, rimantadine, zanamivir, and oseltamivir.

Influenza A virus resistance to amantadine and rimantadine can emerge rapidly during treatment. On the basis of antiviral testing results conducted at CDC and in Canada indicating high levels of resistance, CDC and ACIP recommend that neither amantadine nor rimantadine be used for the treatment or chemoprophylaxis of influenza A in the United States until susceptibility to these antiviral medications has been re-established among circulating influenza A viruses. Oseltamivir or zanamivir can be prescribed if antiviral treatment of influenza is indicated. Oseltamivir is approved for treatment of persons aged >1 year, and zanamivir is approved for treatment of persons aged >7 years. Oseltamivir and zanamivir can be used for chemoprophylaxis of influenza; oseltamivir is licensed for use in persons aged >1 year, and zanamivir is licensed for use in persons aged >5 years.

For more information, consult the following:

Related Links

 

Internet Citation :Antiviral Medications for Influenza



© Copyright 2004 by Community Dispatch.com